Loading news...
/PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announces today that revenue and adjusted EBITA margin for the full year 2025 were
/PRNewswire/ -- Sobi plans to publish its report for the fourth quarter and full year of 2025 on 5 February 2026 at 08:00 CET. Investors, analysts, and the
/PRNewswire/ -- Sobi (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma
/PRNewswire/ -- Sobi (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma
/PRNewswire/ -- Swedish Orphan Biovitrum AB (Sobi) invites investors, analysts, and other stakeholders to its upcoming Capital Markets Day (CMD), which will be
/PRNewswire/ -- Sobi (STO: SOBI) has entered into a definitive agreement to acquire Arthrosi Therapeutics, Inc. (Arthrosi), a private late-stage biotechnology
/PRNewswire/ -- Sobi (STO: SOBI) has entered into a definitive agreement to acquire Arthrosi Therapeutics, Inc. (Arthrosi), a private late-stage biotechnology
/PRNewswire/ -- Sobi (STO: SOBI), today announced its participation at the 65th American Society of Hematology (ASH) Annual Meeting, taking place on 6 - 9
/PRNewswire/ -- Sobi (STO: SOBI) today announced that The New England Journal of Medicine (NEJM) published positive results from the Phase 3 VALIANT study